Skip to main content
DGX
NYSE Industrial Applications And Services

Quest Diagnostics Lifts FY EPS View as Q2 Revenue Tops $3.04B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$225.142
Mkt Cap
$25.228B
52W Low
$165.777
52W High
$237.78
52W Position info
36% above low
Off High info
5.3% below high
Rel. Volume info
4.1× avg
Market data snapshot near publication time

DGX sits 36% above its 52-week low of $165.777 on elevated volume (4.1× avg).

Summary

Quest Diagnostics posted Q2 2026 revenue of $3.04 billion (+10.2% YoY) and raised full-year adjusted EPS guidance to $11.05–$11.25, above consensus, driven by strong volume growth from new partnerships.


Key Events · Earnings and Guidance · DGX

  • Q2 Revenue and Earnings Beat

    Revenue reached $3.04 billion, up 10.2% year-over-year, while adjusted EPS rose 19.1% to $3.12. Both metrics exceeded expectations.

  • Raised Full-Year Guidance

    Management lifted FY adjusted EPS guidance to $11.05–$11.25, above the consensus estimate of $10.95, reflecting confidence in continued growth.

  • Volume Growth Driven by New Partnerships

    Total volume increased 13.1%, with organic growth of 13.0%. Approximately 9% of organic growth came from new relationships with Corewell Health and Fresenius Medical Care.

  • Revenue per Requisition Pressure from Mix

    Revenue per requisition declined 2.8% due to a higher proportion of routine tests from new partnerships. Excluding these, revenue per requisition rose approximately 3%.


Analysis · DGX · Industrial Applications And Services

A strong second quarter saw revenue climb 10.2% to $3.04 billion and adjusted EPS reach $3.12, handily beating expectations. Confidence in the trajectory prompted management to raise full-year adjusted EPS guidance to $11.05–$11.25, above the $10.95 consensus. Volume surged 13.1%, fueled by new partnerships with Corewell Health and Fresenius Medical Care, though revenue per requisition dipped on mix. The balance sheet remains robust following a $500 million debt refinancing and $100 million in share repurchases. With no control or legal concerns, the quarterly report underscores sustained momentum and a constructive outlook, making it highly relevant for investors.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DGX was trading at $225.14 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $165.78 to $237.78. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DGX - Latest Insights

DGX
Oct 23, 2026, 4:18 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $241.89
Real-time Price: $258.50 info
Change: +$16.61 (+7%) info
Market Cap: $28.561B info
DGX
Oct 23, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $238.42
Real-time Price: $258.50 info
Change: +$20.08 (+8%) info
Market Cap: $28.561B info
DGX
Oct 22, 2026, 11:46 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $236.45
Real-time Price: $258.50 info
Change: +$22.05 (+9%) info
Market Cap: $28.561B info
DGX
Oct 22, 2026, 6:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $236.57
Real-time Price: $258.50 info
Change: +$21.93 (+9%) info
Market Cap: $28.561B info
DGX
Oct 22, 2026, 6:49 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $236.57
Real-time Price: $258.50 info
Change: +$21.93 (+9%) info
Market Cap: $28.561B info